China Accepts AP301 NDA
China’s NMPA accepted Alebund Pharmaceuticals’ new drug application for AP301, a non-absorbed fiber-iron phosphate binder for hyperphosphatemia in maintenance-dialysis patients with chronic kidney disease. The filing is supported primarily by the 474-patient, 52-week RESPOND-1…
